Respiratory syncytial virus (RSV) is an important cause of serious respiratory illness in blood and marrow transplant (BMT) recipients. In some subsets of these immunocompromised patients, RSV upper respiratory illnesses frequently progress to fatal viral pneumonia. The frequency of progression to pneumonia is higher during the pre-engraftment than during the postengraftment period. Once pneumonia develops, the overall mortality is 60-80%, regardless of the treatment strategy. We performed a pilot trial of therapy of RSV upper respiratory illnesses using aerosolized ribavirin and IVIG (500 mg/kg every other day), with the goal of preventing progression to pneumonia and death. Two dosages of ribavirin were used: a conventional regimen (6 g/day at 20 mg/ml for 18 h/day) and a high-dose short-duration regimen (6 g/day at 60 mg/ml for 2 h every 8 h). Fourteen patients were treated for a mean of 13 days (range: 7-23 days). In 10 (71%) patients, the upper respiratory illness resolved. The other four (29%) patients, three of whom were in the pre-engraftment period, developed pneumonia, which was fatal in two. The most common adverse effect was psychological distress at being isolated within a scavenging tent. In conclusion, prompt therapy of RSV upper respiratory illnesses in BMT recipients with a combination of aerosolized ribavirin and IVIG was a safe and promising approach to prevent progression to pneumonia and death. Bone Marrow Transplantation (2000) 25, 751-755.
these immunocompromised patients, RSV infections usually present as an upper respiratory illness (URI) which frequently progresses to fatal viral pneumonia. The frequency of progression of URI to pneumonia is higher among patients who are р1 month post transplant or pre-engraftment than patients who are Ͼ1 month post transplant or post engraftment (70-80% vs 25-40%, respectively). 5, 6 Once pneumonia develops, the mortality of untreated RSV pneumonia is over 80%, regardless of the engraftment status. Even with aggressive strategies aimed at promptly treating pneumonias with the currently available drugs, the overall mortality with RSV pneumonia is approximately 60%. 5, 6 A favorable outcome may necessitate the initiation of therapy at an earlier stage of the respiratory illness.
Aerosolized ribavirin is approved by the Food and Drug Administration (FDA) for the therapy of RSV pneumonia in high risk infants and young children. 12 The standard regimen consists of a daily dose of 6 g of ribavirin delivered at a concentration of 20 mg/ml of sterile water for 18 h/day, usually within a scavenging tent to prevent environmental contamination with the drug. Such prolonged aerosol therapy is cumbersome to administer, and difficult for patients to tolerate psychologically. For ease of administration and improved compliance, shorter durations of therapy with higher concentrations of the drug have been investigated. 13, 14 In unintubated children, high-dose short-duration aerosolized ribavirin (6 g/day delivered at a concentration of 60 mg/ml for 2 h every 8 h) has been demonstrated to be safe and to have similar antiviral effects as the standard regimens.
14 This regimen has also been found to be safe in elderly persons with chronic obstructive lung disease. 13 We conducted a pilot trial of combination therapy with aerosolized ribavirin and intravenous immunoglobulin (IVIG) for RSV upper respiratory tract illnesses in adult BMT recipients with the goal of preventing progression to pneumonia and death. Ribavirin was combined with IVIG because studies in vitro, in animal models, and in children had suggested that immunoglobulin may be of benefit for RSV infections prophylactically as well as therapeutically. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] In addition, the University of Texas MD Anderson Cancer Center (MDACC) experience with combination aerosolized ribavirin and IVIG for the therapy of RSV pneumonia in adult BMT recipients and adults with leukemia had been favorable. 6, 8 Bone Marrow Transplantation
Methods
A prospective surveillance study for community respiratory viruses was conducted among adult BMT recipients hospitalized at MDACC, beginning in 1992. 7 Patients with an acute respiratory illness had samples of respiratory secretions obtained for viral culture and rapid RSV antigen assay by means of ELISA and/or indirect immunofluorescence. In most cases, specimens consisted of combined nasopharyngeal washes and throat swabs (NPW/T). When available, endotracheal aspirates from intubated patients and bronchoalveolar lavage (BAL) fluids were also sampled.
A minimum of 3 ml of fluid was inoculated into 1-3 ml of viral transport media. Specimens were transported on ice and inoculated within 4 h of collection on to tissue cultures (Madin-Darby canine kidney cells, rhesus monkey kidney continuous cell line (LLC-MK 2 ), human laryngeal tumor cells (Hep-2) and human embryonic lung fibroblasts (WI-38)). RSV was identified by characteristic cytopathic effect in cell cultures and confirmed by staining with a fluorescein-conjugated polyclonal Ab. Only cases confirmed by culture or histopathology are included in this analysis.
The trial extended from the winter of 1992-1993 to the winter of 1996-1997. Therapy consisted of a daily dose of 6 g of ribavirin aerosolized via a small particle aerosol generator (SPAG-2) and administered via a face mask, and IVIG at 500 mg/kg every other day for the duration of therapy. In the initial five patients, ribavirin was administered at a concentration of 20 mg/ml for 18 h a day. In the subsequent nine patients, ribavirin was administered at 60 mg/ml for 2 h every 8 h. If the patient developed pneumonia, the high-dose short-duration regimen of ribavirin was changed to the standard regimen. The length of therapy was individualized according to the underlying immunologic status of the patient, clinical response and the duration of viral shedding. To avoid drug-related bronchospasm, inhalational bronchodilator therapy was administered every 4 h.
An acute URI was defined as the recent onset of rhinorrhea, nasal or sinus congestion, otitis media, pharyngitis, and /or cough with a clear chest radiograph. Pneumonia was defined as an acute respiratory illness occurring in association with signs and/or symptoms of lower respiratory tract disease and a new radiographic infiltrate. Neutropenia was defined as р500 neutrophils/ml of blood. Engraftment was defined as the resolution of neutropenia after transplantation. An infection was considered to be nosocomial if symptoms developed у7 days after hospital admission.
Results
During five winter seasons, from 1992-1993 to 1996-1997, 14 adult BMT recipients with RSV upper respiratory illnesses were treated with a combination of aerosolized ribavirin and IVIG for a mean of 13 days (range 7-23 days). The infections occurred in a fall-winter seasonal pattern. There were three, five, four, none and two cases, respectively, during each winter. The clinical characteristics of these patients are summarized in Table 1 . Seven patients were pre-engraftment at the onset of respiratory symptoms. The most common signs and symptoms were cough (100%), sputum (86%), rhinorrhea (86%), sinus congestion (79%) and rales or rhonchi (79%). Fifty percent of the patients had fever. Sinusitis was documented in three of four patients who underwent radiographic evaluation. The method of diagnosing RSV infection was by culture and rapid RSV Ag (n = 10); culture alone (n = 3), and rapid RSV Ag and histopathology (n = 1).
In 10 (71%) patients, the URI resolved after a mean of 22 days (range 11-54 days) ( Table 2 ). These 10 patients were treated for a mean of 11 days (range 7-18 days) beginning at a mean of 8 days (range 2-39 days) after the onset of symptoms. The mean duration of viral shedding was 10 days (range 1-19 days). RSV was identified in the following specimens: NPW/T (nine patients) and NPW/T and BAL (one patient who had tracheobronchitis without radiographic infiltrates ( Table 1) .
The other four (29%) patients developed pneumonia associated with bilateral interstitial infiltrates on chest radiograph, two of which were fatal. These four patients had hematological malignancies and were р15 days post transplant when symptoms began. Three patients had not yet engrafted. These four patients were treated for a mean of 18 days (range 14-23 days) beginning at a mean of 6 days (range 3-7 days) after the onset of symptoms. The Table 1 Characteristics and outcome of 14 adult blood and marrow transplant recipients with RSV upper respiratory tract illnesses treated with combination aerosolized ribavirin and intravenous immunoglobulin mean duration of illnesses was 28 days (range 23-34 days).
The mean duration of viral shedding was 16 days (range 1-30 days). RSV was identified in the following specimens: NPW/T (one patient); NPW/T and BAL (two patients who had developed pneumonia when the BAL specimen was obtained); and BAL and post-mortem lung tissue (one patient who had tracheobronchitis without radiographic infiltrates when the BAL specimen was obtained). The two patients with pneumonia who survived had other potentially important pathogens isolated: one patient had Torulopsis glabrata and Pseudomonas aeruginosa isolated from sputum and Enterococcus spp. isolated from blood; the other patient had herpes simplex virus isolated from a nasopharyngeal wash/ throat swab. The two patients with pneumonia who died did not have any other pathogens identified pre-or post-mortem. One of these patients had prolonged pancytopenia related to graft failure. URI symptoms developed 14 days after receiving an autologous BMT for CLL, and pneumonia developed 18 days after the onset of URI symptoms and 11 days after the initiation of antiviral therapy. Death occurred 23 days after the onset of URI symptoms. Autopsy was not performed. The second patient developed URI symptoms 15 days after receiving an autologous BMT for lymphoma, post engraftment. Therapy was continued for 14 days with full resolution of symptoms and multiple negative follow-up cultures. One month later, the patient died of rapidly progressive RSV pneumonia documented at autopsy. It was unclear whether this pneumonia constituted a relapse of the previous RSV infection or a reinfection.
All patients tolerated the full course of therapy. The following adverse effects were noted. All 14 patients complained of 'hail' and/or 'snowflakes' and/or 'thick smog' blowing into their faces. In all cases, this was minimized to a tolerable level with the assistance of the respiratory therapists. All patients complained of loneliness and anxiety due to confinement within the scavenging tent. Five of these patients required psychiatric consultation (two of the Bone Marrow Transplantation nine patients receiving the 6 h/day regimen and three of the five patients receiving the 18 h/day regimen). Two patients (one in each group) complained of increased cough during the treatment, one of whom also had increased wheezing. One patient with extensive lymphomatous involvement of the head and neck region required an elective tracheotomy after 9 days of administering the highdose aerosol via a face mask in order to administer the aerosol more comfortably. No hematological or hepatic dysfunction was attributed to the drug.
Discussion
In these high risk immunocompromised patients, prompt therapy of RSV upper respiratory illnesses with a combination of aerosolized ribavirin and IVIG was relatively well tolerated and appeared to impact favorably on the frequency of progression to pneumonia and death. Only four (29%) patients developed pneumonia and only two (14%) patients died. The frequency of progression to pneumonia was higher in pre-engrafted than post-engrafted patients although both were less than generally reported. Among the seven pre-engrafted patients, three (43%) patients developed pneumonia and one (14%) died. Among the seven post-engrafted patients, only one (14%) patient developed pneumonia, and one (14%) died.
The high-dose short-duration regimen was better tolerated because it enabled the patient to spend less time physically and psychologically isolated inside scavenging tents. It also enabled less cumbersome care by the hospital staff and more frequent visitation by family members and friends. Although all patients initially had a sensation of precipitated drug blowing into their faces, it was possible to reduce this to a tolerable level in all cases. Bronchospasm was seldom a problem with the aggressive bronchodilator therapy used in these patients.
In a similar open trial conducted at the Fred Hutchinson Cancer Research Center, 25 BMT recipients with RSV upper respiratory illnesses were treated with a lower daily dose of aerosolized ribavirin and a shorter duration of therapy (2 g of ribavirin were administered at a concentration of 60 mg/ml for 2 h each day). 9 The advantage of this regimen was that it could be administered in an outpatient setting. Eight (32%) patients developed pneumonia, seven (88%) of whom died. Subgrouping into pre-and post engraftment was not reported. Compared with the larger doses and longer durations of therapy at MDACC, the overall results appear similar in terms of the frequency of progression to pneumonia (32% vs 29%, respectively). Although the overall mortality was twice as high in the FHCRC study (28% vs 14%, respectively), the number of cases was too small to draw any conclusions. Other studies involving small numbers of patients have also reported on the favorable outcome of BMT recipients with RSV infections treated promptly with aerosolized ribavirin at the URI stage or at the stage of clinical but not radiographically evident acute lung injury. 3, 34 Studies to date are limited by the lack of randomized controls, and are not directly comparable because of differences in the underlying immunodeficiencies, differences in Bone Marrow Transplantation the treatment regimens, and differences in whether the therapy was administered in the inpatient or outpatient setting. Overall, the data suggest that the frequency of progression to pneumonia and the mortality can be diminished by promptly treating URIs with ribavirin. Whether larger doses, longer durations or higher concentrations of ribavirin therapy are of added benefit will need to be evaluated in larger, controlled trials, as will the benefit of combining ribavirin with immune therapy. Since the morbidity and mortality associated with RSV upper respiratory illnesses was still considerable in spite of prompt therapy of URIs, the need to investigate prophylactic strategies in BMT recipients is apparent.
The role of high RSV titered IVIG or RSV monoclonal Ab in the prophylaxis or therapy of RSV infections in immunocompromised patients remains to be defined. 6, [27] [28] [29] [30] [31] [32] [33] The commercially available forms of these drugs are RespiGam (MedImmune, Gaithersburg, MD, USA), a pooled human polyclonal IgG intravenous hyperimmune globulin with high RSV microneutralization titers and Synagis (MedImmune), an intramuscularly administered humanized monoclonal Ab directed against the F glycoprotein of RSV. These drugs have been approved by the FDA for prophylaxis against serious complications of RSV infection in high risk infants and young children in January 1996 and June 1998. These drugs are prohibitively expensive to administer to adult-sized patients. Efficacy will need to be demonstrated in controlled trials before routine use of these drugs can be considered in adults.
In conclusion, uncontrolled trials reported to date support the concept of treating high risk immunocompromised patients infected with RSV at an early stage of the respiratory illness. The cost and cumbersomeness associated with the currently available therapies render this a difficult undertaking, particularly as this infection is so common and so frequently self-limited. Controlled clinical trials are needed to confirm the efficacy of aerosolized ribavirin with or without standard IVIG, high RSV titered IVIG or monoclonal RSV antibody as well as to define risk factors for progressive disease so that therapy can be targeted appropriately.
The cumulative experience from several transplant centers suggests that the patients at highest risk for severe RSV disease are those who are early post transplant or not yet engrafted. These patients have a 70-80% risk of disease progression, and need to be proactively identified and treated. The subsets of patients who are later post transplant or post-engraftment who require treatment are less welldefined. Although the frequency of progression of URI to pneumonia in these patients has been reported to be approximately 25-40%, these figures are likely to represent a considerable overestimate since many BMT recipients (particularly autologous BMT recipients) are followed less closely in the late post-transplant period. The tendency has been for more immunosuppressed patients and more serious respiratory illnesses to come to medical attention. Because host immunity plays a dominating role in the recovery from RSV infections, the benefit of any intervention in the postengraftment period will be especially difficult to evaluate outside of a controlled trial. Given the available data, it is the current practice at MDACC to individualize care for post-engrafted BMT recipients with RSV upper respiratory illnesses based on a constellation of risk factors for progressive disease including an estimate of the patient's net level of immunosuppression (considering factors such as underlying disease, type of transplant, time after transplant, presence of GVHD, immunosuppressive therapies, leukocyte count); the age of the patient; the stage of the URI (searching for clinical evidence of radiographically not visible lower respiratory tract disease); the clinical course of the respiratory illness over the preceding few days; and the presence of underlying lung disease. Using this approach, the ratio of untreated to treated post-engrafted BMT recipients with documented RSV upper respiratory illnesses in our center has been approximately 3:1. All of our postengrafted BMT recipients with documented RSV upper respiratory illnesses who have not received specific antiviral therapy because they were judged to be at low risk for progression to viral pneumonia have survived.
